260 related articles for article (PubMed ID: 20180618)
1. Orexin receptor antagonists: a review of promising compounds patented since 2006.
Coleman PJ; Renger JJ
Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
[TBL] [Abstract][Full Text] [Related]
2. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
Neubauer DN
Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
[TBL] [Abstract][Full Text] [Related]
3. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
4. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.
Gotter AL; Webber AL; Coleman PJ; Renger JJ; Winrow CJ
Pharmacol Rev; 2012 Jul; 64(3):389-420. PubMed ID: 22759794
[TBL] [Abstract][Full Text] [Related]
5. Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure.
Winrow CJ; Tanis KQ; Reiss DR; Rigby AM; Uslaner JM; Uebele VN; Doran SM; Fox SV; Garson SL; Gotter AL; Levine DM; Roecker AJ; Coleman PJ; Koblan KS; Renger JJ
Neuropharmacology; 2010 Jan; 58(1):185-94. PubMed ID: 19596018
[TBL] [Abstract][Full Text] [Related]
6. Orexin receptor antagonists: medicinal chemistry and therapeutic potential.
Roecker AJ; Coleman PJ
Curr Top Med Chem; 2008; 8(11):977-87. PubMed ID: 18673167
[TBL] [Abstract][Full Text] [Related]
7. Orexin receptor antagonists.
Christopher JA
Pharm Pat Anal; 2012 Jul; 1(3):329-46. PubMed ID: 24236845
[TBL] [Abstract][Full Text] [Related]
8. Orexin receptors: pharmacology and therapeutic opportunities.
Scammell TE; Winrow CJ
Annu Rev Pharmacol Toxicol; 2011; 51():243-66. PubMed ID: 21034217
[TBL] [Abstract][Full Text] [Related]
9. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
10. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
Coleman PJ; Cox CD; Roecker AJ
Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists.
Coleman PJ; Schreier JD; McGaughey GB; Bogusky MJ; Cox CD; Hartman GD; Ball RG; Harrell CM; Reiss DR; Prueksaritanont T; Winrow CJ; Renger JJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2311-5. PubMed ID: 20207138
[TBL] [Abstract][Full Text] [Related]
12. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.
Bettica P; Nucci G; Pyke C; Squassante L; Zamuner S; Ratti E; Gomeni R; Alexander R
J Psychopharmacol; 2012 Aug; 26(8):1058-70. PubMed ID: 21730017
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule antagonists of the orexin receptors.
Christopher JA
Pharm Pat Anal; 2014; 3(6):625-38. PubMed ID: 25489915
[TBL] [Abstract][Full Text] [Related]
15. P2X purinergic receptor ligands: recently patented compounds.
Gunosewoyo H; Kassiou M
Expert Opin Ther Pat; 2010 May; 20(5):625-46. PubMed ID: 20205618
[TBL] [Abstract][Full Text] [Related]
16. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
[TBL] [Abstract][Full Text] [Related]
17. Orexin receptor antagonists--a patent review (2010 to August 2014).
Boss C
Expert Opin Ther Pat; 2014 Dec; 24(12):1367-81. PubMed ID: 25407283
[TBL] [Abstract][Full Text] [Related]
18. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists.
Tran DT; Bonaventure P; Hack M; Mirzadegan T; Dvorak C; Letavic M; Carruthers N; Lovenberg T; Sutton SW
Eur J Pharmacol; 2011 Sep; 667(1-3):120-8. PubMed ID: 21679703
[TBL] [Abstract][Full Text] [Related]
19. Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692).
Christopher JA; Congreve MS
Expert Opin Ther Pat; 2013 Feb; 23(2):273-7. PubMed ID: 23282091
[TBL] [Abstract][Full Text] [Related]
20. [Present status and future of hypnotic drug treatment for insomnia].
Uchiyama M; Konno M
Nihon Rinsho; 2012 Jul; 70(7):1241-51. PubMed ID: 22844812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
